Temporal pediatric sepsis biomarker risk model

Abstract

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

What is claimed is: 
     
         1 . A method of monitoring the therapeutic efficacy of a first treatment administered to a patient with septic shock, and administering to the patient a second treatment, the method comprising:
 analyzing a first sample that has been obtained from the patient at a first time point, which is during day 1 of presentation with septic shock and before the first treatment has been administered, to determine a first serum concentration level of each of two biomarkers consisting of C-C chemokine ligand 3 (CCL3) and interleukin-8 (IL8);   analyzing a second sample that has been obtained from the patient at a second time point, which is during day 3 of presentation with septic shock and after the first treatment has been administered to the patient, to determine a second serum concentration level of each of the biomarkers;   determining whether the level of each biomarker is elevated above a cut-off level at each of the first and second time points,   identifying the patient as at high risk for a poor outcome where any one of the following is true:   a) a non-elevated level of CCL3 and an elevated level of IL8 at the first time point, and a highly elevated level of IL8 at the second time point, or   b) a highly elevated level of CCL3 at the first time point, and a non-elevated level of IL8 at the second time point, or   c) an elevated level of CCL3 and a highly elevated level of IL8 at the first time point, and an elevated level of IL8 at the second time point; and   discontinuing administration of the first treatment and administering to the patient identified as at high risk for a poor outcome a second treatment selected from one or more of extracorporeal membrane oxygenation/life support, plasmapheresis, pulmonary artery catheterization, and high volume continuous hemofiltration.   
     
     
         2 . The method of  claim 1 , further comprising analyzing the second sample for a third biomarker, heat shock protein 70 kDa (HSPA1B) and identifying the patient as at high risk for a poor outcome where the patient has an elevated level of CCL3 and a non-highly elevated level of IL8 at the first time point, and elevated levels of IL8 and HSPA1B at the second time point. 
     
     
         3 . The method of  claim 1 , further comprising obtaining at least one additional sample(s) from the patient after a treatment has been administered to the patient and analyzing the at least one additional sample for the level of CCL, IL8, or HSPA1B. 
     
     
         4 . The method of  claim 3 , wherein the at least one additional sample is obtained 12-36 hours after the second time point. 
     
     
         5 . The method of  claim 3 , wherein the at least one additional sample is obtained within the first 60 hours of presentation with septic shock. 
     
     
         6 . The method of  claim 1 , wherein
 a) an elevated level of CCL3 at the first time point corresponds to a serum CCL3 concentration greater than 130 pg/ml,   b) a highly elevated level of CCL3 at the first time point corresponds to a serum CCL3 concentration greater than 216 pg/ml,   c) an elevated level of IL8 at the first time point corresponds to a serum IL8 concentration greater than 125 pg/ml,   d) a highly elevated level of IL8 at the first time point corresponds to a serum IL8 concentration greater than 436 pg/ml,   e) an elevated level of IL8 at the second time point corresponds to a serum IL8 concentration greater than 33 pg/ml, and   f) a highly elevated level of IL8 at the second time point corresponds to a scrum IL8 concentration greater than 123 pg/ml.   
     
     
         7 . The method of  claim 2 , wherein an elevated level of HSPA1B at the second time point corresponds to a serum HSPA1B concentration greater than 1.20 μg/ml. 
     
     
         8 . The method of  claim 1 , wherein the method further comprises receiving one or more patient demographic data and/or clinical characteristics and/or results from other tests or indicia of septic shock. 
     
     
         9 . The method of  claim 8 , wherein
 a) the patient demographic data comprises the age of the patient, or   b) wherein the patient demographic data and/or clinical characteristics and/or results from other tests or indicia of septic shock comprises the septic shock causative organism, the presence or absence of chronic disease, and/or the gender, race, and/or co-morbidities of the patient.   
     
     
         10 . The method of  claim 1 , wherein the determination of whether the level(s) of the one or more biomarkers are elevated is combined with one or more additional population-based risk scores. 
     
     
         11 . The method of  claim 10 , wherein the one or more population-based risk scores comprises pediatric risk of mortality (PRISM) and/or pediatric index of mortality (PIM).